(Q72686737)
Statements
A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy (English)
L T Goodnough
T H Price
K D Friedman
M Johnston
D Ciavarella
N Khan
R Sacher
W R Vogler
M Wissel